BIO

Josh Peters, Ph.D. is CEO and co-founder of Prox Biosciences. Prior to Prox, he was a Venture Associate at 82VS, where he contributed to early-stage discovery and development of three novel therapeutics in oncology and ophthalmology. Before that, he was a Senior Associate at BrightEdge and contributed to fifteen strategic investments across diagnostics, manufacturing, digital health, and therapeutics. He earned his Ph.D. from the Department of Biological Engineering at MIT as a Presidential Fellow, focusing on immunogenomics, and his B.S. in Chemical Engineering from the University of Pittsburgh, focusing on pharmacokinetics and biomarker discovery as an Amgen Scholar.